Showing results (31-40 of 36) with videos related to
Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 36 results.
Molecular Cancer Therapeutics|October 25, 2019
A Phase I Study of LY3009120, a Pan-RAF Inhibitor, in Patients with Advanced or Metastatic CancerRyan J Sullivan, Antoine Hollebecque, Keith T Flaherty, et al.Molecular Cancer Therapeutics|August 20, 2015
Altiratinib Inhibits Tumor Growth, Invasion, Angiogenesis, and Microenvironment-Mediated Drug Resistance via Balanced Inhibition of MET, TIE2, and VEGFR2Bryan D Smith, Michael D Kaufman, Cynthia B Leary, et al.Cancer Cell|September 8, 2015
Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant CancersSheng-Bin Peng, James R Henry, Michael D Kaufman, et al.Cancer Cell|April 13, 2011
Conformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor DCC-2036Wayne W Chan, Scott C Wise, Michael D Kaufman, et al.Cancer Cell|May 16, 2019
Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA VariantsBryan D Smith, Michael D Kaufman, Wei-Ping Lu, et al.Journal of Medicinal Chemistry|May 13, 2015
Discovery of 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea (LY3009120) as a pan-RAF inhibitor with minimal paradoxical activation and activity against BRAF or RAS mutant tumor cellsJames R Henry, Michael D Kaufman, Sheng-Bin Peng, et al.Pageof 4